$LUCD Cashflow Statement | Understand Stock

$LUCD

$0.44 -$0.06 (12.5%) Close

$LUCD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Depreciation expense
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense
Stock-based compensation
Lucid Diagnostics 2018 Equity Plan
PAVmed 2014 Equity Plan
Total stock-based compensation
Stock-based compensation - PAVmed Inc. 2014 Equity Plan
APA-RDx: Issue common stock - settle installment payment
Loss on issue - Senior Secured Convertible Note
Change in fair value - Senior Secured Convertible Note
Debt extinguishment loss - Senior Secured Convertible Note
APA-RDx: Issue common stock - termination payment
Issue common stock - vendor service agreement
Amortization of common stock payment for vendor service agreement
Equity issuance cost extinguishment

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Accrued CWRU License Agreement Fee
Due To: PAVmed Inc. - operating expenses paid on-behalf-of Lucid Diagnostics Inc.
Due To: PAVmed Inc. - Management Services Agreement Fee
Due To: PAVmed Inc. - Operating expenses
Due To: PAVmed Inc. - Employee Related Costs
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee
Net cash flows used in operating activities

Cash flows from investing activities
Purchase of equipment
Purchase of intellectual property from PAVmed Inc.
PAVmed
Total purchase of intellectual property from PAVmed Inc.
Net cash flows used in investing activities
Cash flows from financing activities
Proceeds – issue of common stock – initial public offering
Proceeds – issue of preferred stock
Payment – offering costs – initial public offering
Proceeds – issue of Senior Secured Convertible Notes
Payment – repayment of Senior Secured Convertible Note
Proceeds – issue of common stock – At-The-Market Facility
Proceeds – exercise of stock options
Proceeds – issue common stock – Employee Stock Purchase Plan
Proceeds – Due To: PAVmed Inc. - working capital cash advances
Net cash flows provided by financing activities
Net increase (decrease) in cash
Cash, beginning of period
Cash, end of period

Comments